Translation of imaging biomarkers from clinical research to healthcare

  • Ingo Kilimann
  • Jochen René Thyrian
  • Wolfgang Hoffmann
  • Stefan J. Teipel
Beiträge zum Themenschwerpunkt


The use of biomarkers for diagnostics of Alzheimer’s disease (AD) has increased over the last years in specialized care and experimental settings. With the possibly upcoming availability of disease-modifying therapeutic agents, the diagnostics and treatment of patients with cognitive impairment will change. Biomarkers will be used as theranostic markers for case finding. The development and evaluation of biomarkers can be framed in a phase model from preclinical studies through trials in expert center settings to the evaluation of biomarkers in primary care, up to testing the efficacy and the impact of biomarkers on the healthcare system. Hippocampal volumetry is the most accepted and in-depth tested biomarker for AD diagnostics and prediction of the course. Therefore, hippocampus volumetry is used to illustrate the phase model of biomarker development and present the milestones already achieved and questions still to be resolved.


Alzheimer disease Amyloid Tau Positron emission tomography Cerebrospinal fluid 

Translation bildgebender Biomarker von klinischen Studien bis zur Gesundheitsversorgung


Die Diagnostik der Alzheimer-Krankheit an spezialisierten Zentren hat sich bereits durch die vermehrte Nutzung von Biomarkern verändert. Eine eventuell in den nächsten Jahren bevorstehende Zulassung von krankheitsmodifizierenden Medikamenten zur Behandlung der Alzheimer Krankheit wird den Ablauf der Regeldiagnostik beeinflussen. Biomarker werden dann als wichtiges Theranostikum benötigt. Ein Phasenmodell beschreibt die Entwicklung und Erprobung von Biomarkern von der präklinischen Suche nach möglichen Zielmarkern über wissenschaftliche Untersuchungen in experimentellen Stichproben bis hin zur Erprobung der Effektivität eines Biomarkers in der Primärversorgung. Der bisher am umfangreichsten untersuchte Biomarker zur Diagnostik und Prädiktion des Verlaufs einer Alzheimer-Krankheit ist das Volumen des Hippokampus. Anhand der Hippokampusvolumetrie werden die bereits erreichten Meilensteine aufgezeigt und die noch offenen Fragen bei der Entwicklung von Biomarkern für die Alzheimer-Krankheit dargestellt.


Morbus Alzheimer Amyloid Tau Positronenemissionstomographie (PET) Zerebrospinalflüssigkeit 


Compliance with ethical guidelines

Conflict of interests

I. Kilimann, J.R. Thyrian, W. Hoffmann and S.J. Teipel declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors.

The supplement containing this article is not sponsored by industry.


  1. 1.
    Albert MS, Dekosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Anonymous (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRefGoogle Scholar
  3. 3.
    Ball MJ (1977) Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol 37:111–118CrossRefPubMedGoogle Scholar
  4. 4.
    Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRefGoogle Scholar
  5. 5.
    Bobinski M, De Leon MJ, Wegiel J et al (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience 95:721–725CrossRefPubMedGoogle Scholar
  6. 6.
    Boccardi M, Ganzola R, Bocchetta M et al (2011) Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. J Alzheimers Dis 26(Suppl 3):61–75PubMedGoogle Scholar
  7. 7.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMedGoogle Scholar
  8. 8.
    Brueggen K, Dyrba M, Barkhof F et al (2015) Basal forebrain and hippocampus as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment – A multicenter DTI and volumetry study. J Alzheimers Dis 48:197–204CrossRefPubMedGoogle Scholar
  9. 9.
    Clerx L, Van Rossum IA, Burns L et al (2013) Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiol Aging 34:2003–2013CrossRefPubMedGoogle Scholar
  10. 10.
    De Leon MJ, George AE, Stylopoulos LA et al (1989) Early marker for Alzheimer’s disease: the atrophic hippocampus. Lancet 2:672–673CrossRefPubMedGoogle Scholar
  11. 11.
    De Leon MJ, Golomb J, George AE et al (1993) The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol 14:897–906PubMedGoogle Scholar
  12. 12.
    Frisoni GB, Jack CR Jr., Bocchetta M et al (2015) The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement 11:111–125CrossRefPubMedGoogle Scholar
  13. 13.
    Galluzzi S, Geroldi C, Ghidoni R et al (2010) The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257:2004–2014CrossRefPubMedGoogle Scholar
  14. 14.
    Gosche KM, Mortimer JA, Smith CD et al (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58:1476–1482CrossRefPubMedGoogle Scholar
  15. 15.
    Hampel H, Prvulovic D, Teipel S et al (2011) The future of Alzheimer’s disease: the next 10 years. Prog Neurobiol 95:718–728CrossRefPubMedGoogle Scholar
  16. 16.
    Jack CR Jr., Dickson DW, Parisi JE et al (2002) Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58:750–757CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kesslak JP, Nalcioglu O, Cotman CW (1991) Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology 41:51–54CrossRefPubMedGoogle Scholar
  18. 18.
    Mckhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Panza F, Seripa D, Solfrizzi V et al (2016) Emerging drugs to reduce abnormal beta-amyloid protein in Alzheimer’s disease patients. Expert Opin Emerg Drugs. doi: 10.1080/14728214.2016.1241232 PubMedGoogle Scholar
  20. 20.
    Pepe MS, Cai T, Longton G (2006) Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 62:221–229CrossRefPubMedGoogle Scholar
  21. 21.
    Pepe MS, Etzioni R, Feng Z et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054–1061CrossRefPubMedGoogle Scholar
  22. 22.
    Risacher SL, Saykin AJ, West JD et al (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6:347–361CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schuff N, Woerner N, Boreta L et al (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Teipel S, Drzezga A, Grothe MJ et al (2015) Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol 14:1037–1053CrossRefPubMedGoogle Scholar
  25. 25.
    Teipel SJ, Keller F, Thyrian JR et al (2017) Hippocampus and basal forebrain volumetry for dementia and mild cognitive impairment diagnosis: could it be useful in primary care? J Alzheimers Dis 55:1379–1394CrossRefPubMedGoogle Scholar
  26. 26.
    Thyrian JR, Fiss T, Dreier A et al (2012) Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials 13:56CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Varon D, Barker W, Loewenstein D et al (2015) Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. Int J Geriatr Psychiatry 30:192–200CrossRefPubMedGoogle Scholar
  28. 28.
    Wolf D, Bocchetta M, Preboske GM et al (2017) Reference standard space hippocampus labels according to the EADC-ADNI harmonized protocol: Utility in automated volumetry. Alzheimers Dement. doi: 10.1016/j.jalz.2017.01.009 PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • Ingo Kilimann
    • 1
    • 2
  • Jochen René Thyrian
    • 1
  • Wolfgang Hoffmann
    • 3
    • 4
  • Stefan J. Teipel
    • 1
    • 2
  1. 1.German Center for Neurodegenerative Disease (DZNE) Rostock/GreifswaldRostockGermany
  2. 2.University Hospital RostockUniversity RostockRostockGermany
  3. 3.Institute for Community MedicineUniversity Hospital GreifswaldGreifswaldGermany
  4. 4.German Center for Neurodegenerative Disease (DZNE) Rostock/GreifswaldGreifswaldGermany

Personalised recommendations